20 citations,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
9 citations,
April 2021 in “Expert opinion on pharmacotherapy” Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
[object Object] 44 citations,
October 2009 in “Journal of the American Academy of Dermatology” Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
69 citations,
April 2010 in “Dermatologic Surgery” Bimatoprost is a safe and effective treatment for making eyelashes longer, thicker, and darker.
50 citations,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
116 citations,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
36 citations,
June 2017 in “Journal of Cutaneous Medicine and Surgery” The consensus document recommends a comprehensive treatment plan for Hidradenitis Suppurativa, including various medications, surgery, lifestyle changes, and the need for more research and resources.
19 citations,
October 2011 in “Clinics in Dermatology” New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
May 2024 in “Aktualʹnì problemi sučasnoï medicini: Vìsnik Ukraïnsʹkoï medičnoï stomatologìčnoï akademì” Spironolactone and clascoterone are promising acne treatments with fewer side effects.
4 citations,
September 2012 in “Clinical Pharmacology in Drug Development” Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.
[object Object] July 2021 in “Medical journal, Armed Forces India” Using platelet-rich plasma in hair restoration surgery significantly improves hair density after 6 months and is safe to use.
There are many treatments for common hair loss, but more trials are needed to decide which are best.
6 citations,
June 2011 in “British Journal of Dermatology” People with alopecia areata have higher levels of RBP4 protein and antibodies against it.
March 2024 in “Clinical and experimental dermatology” Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.
65 citations,
January 2013 in “Cochrane library” Some systemic treatments work for nail psoriasis but can have serious side effects.
40 citations,
December 2019 in “Neurobiology of Stress” Neuroactive steroids show promise for treating mental and neurological disorders by targeting GABA_A receptors.
March 2024 in “International journal of pharmaceutical sciences and drug research” Androgenetic alopecia is influenced by various factors and can be treated with medications, procedures, and non-drug methods.
February 2024 in “International Journal of Molecular Sciences” Hair loss in Androgenetic Alopecia is caused by genetics, aging, and lifestyle, leading to hair follicle shrinkage and related health risks.
January 2022 in “Springer eBooks” 19 citations,
May 2016 in “Clinical, cosmetic and investigational dermatology” FGF-2&D/P nanoparticles can help treat hair loss.
5 citations,
May 2020 in “Clinical and Experimental Dermatology” Clascoterone may be a promising treatment for hair loss.
44 citations,
August 1996 in “Drugs & Aging” Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.
May 2024 in “Frontiers in Immunology” This mini-review examines the role of type-2 immunity in type-1-related skin inflammatory diseases, such as alopecia areata (AA), vitiligo, and localized scleroderma (LS). It reveals that while type-1 immunity is traditionally associated with these conditions, type-2 immunity also plays a significant role. In LS, type-2 cytokines like IL-4 and IL-13 are linked to fibrosis, and in AA, elevated type-2 markers suggest involvement in disease pathogenesis. The review highlights the potential of treatments targeting type-2 responses, such as JAK inhibitors and therapies focusing on the IL-4/IL-13 axis, which show promise in specific patient subsets. Further research is needed to understand whether type-2 immunity is protective or detrimental in these diseases, which could improve patient stratification for targeted therapies.
1 citations,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
4 citations,
February 2019 in “PubMed” Clascoterone may be an effective topical treatment for hair loss.
April 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” Certain surgical methods are better than routine incision for hidradenitis suppurativa, topical clindamycin and acitretin are effective treatments, men with HS have a risk of skin cancer, HS patients are more likely to die from heart problems, and specific genetic markers are linked to treatment response.
September 2024 in “Current Oncology” Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.
1 citations,
March 2023 in “Nutrients” The conclusion is that obesity should be managed with a slow, balanced approach to diet and exercise, with medication and surgery as additional options, and education and access to care are important.
January 2025 in “Dermatology and Therapy” Hormonal therapies effectively treat acne and improve quality of life.
2 citations,
February 2023 in “BJUI” Urologists should monitor mental health in patients taking finasteride due to potential links to suicidal thoughts, adjusting dosage or stopping use if necessary. More research is needed to confirm if finasteride causes these thoughts.